Kynam Capital Management, LP
PRINCETON, NJ · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.81B2026 Q3
Positions34
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.72.3%
What Changed This Quarter?
Top Holdings
LEGN
Legend Biotech
10.1%
CLDX
Celldex Therapeutics
9.1%
SNDX
Syndax Pharmaceuticals
8.5%
PCVX
Vaxcyte
8.2%
VRDN
Viridian Therapeutics
7.0%
COGT
Cogent Biosciences
6.7%
TVTX
Travere Therapeutics
6.5%
URGN
UroGen Pharma
5.5%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.